AbbVie Inc. buy RudolfL
Start price
06.11.21
/
60%
€101.66
Target price
06.11.22
€170.00
Performance (%)
39.17%
End price
29.04.22
€141.48
Summary
This prediction ended on 29.04.22 with a price of €141.48. The BUY prediction by RudolfL for AbbVie Inc. saw massive gains of 39.17%. RudolfL has a follow-up prediction for AbbVie Inc. where he still thinks AbbVie Inc. is a Buy. A total of €2.52 was paid as dividends for this prediction. RudolfL has 60% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| AbbVie Inc. | 2.373% | 2.373% | 6.114% |
| iShares Core DAX® | -0.870% | -1.700% | 10.560% |
| iShares Nasdaq 100 | -5.561% | -3.604% | 34.335% |
| iShares Nikkei 225® | -6.138% | -7.732% | 16.215% |
| iShares S&P 500 | -3.141% | -2.011% | 24.534% |
Comments by RudolfL for this prediction
In the thread AbbVie Inc. diskutieren
Kursziel geändert auf 170,0